Deals In Depth: January 2013
Executive Summary
Gilead licensed rights to four preclinical antibodies from MacroGenics. Stryker bought Chinese device company Trauson for $751 million. Biopharma companies raised double the amount from December, bringing in $2.8 billion, while device funding dropped to $269 million.
You may also be interested in...
Does Polivy Provide A Cure For DLBCL? Too Early To Say, Argue NICE Experts
Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.
Back With A Bang: ‘Brexit Bill’ For UK’s Medical Devices Due For 2nd Reading On 2 March
Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.
EU Funding For COVID-19 Drug & Diagnostic Research
Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports